- Home
- NFE vs LRMR Comparison
NFE vs LRMR Comparison
Compare NFE & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | LRMR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 332.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | NFE | LRMR |
|---|---|---|
| Price | $1.27 | $4.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.70 | ★ $16.71 |
| AVG Volume (30 Days) | ★ 16.5M | 1.4M |
| Earning Date | 12-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,768,624,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $1.61 |
| 52 Week High | $16.66 | $6.48 |
Technical Indicators
Market Signals| Indicator | NFE | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 58.90 |
| Support Level | $1.21 | $3.12 |
| Resistance Level | $1.70 | $4.09 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 32.81 | 96.49 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.